FDA Oncology Announcements

Anti-BCMA-CD3 bispecific × Clear all

4 Announcements

FDA approves teclistamab in combination with daratumumab hyaluronidase-fihj for relapsed or refractory multiple myeloma

Trial: MajesTEC-3
Drugs: Tecvayli (teclistamab) · Anti-BCMA-CD3 bispecific antibody, daratumumab hyaluronidase-fihj · Anti-CD38 antibody
Condition: Plasma cell

FDA grants accelerated approval to linvoseltamab-gcpt for relapsed or refractory multiple myeloma

Trial: LINKER-MM1
Drug: Lynozyfic (linvoseltamab-gcpt) · Anti-BCMA-CD3 bispecific antibody
Condition: Plasma cell

FDA grants accelerated approval to elranatamab-bcmm for multiple myeloma

Drug: Elrexfio (elranatamab-bcmm) · Anti-BCMA-CD3 bispecific antibody
Condition: Plasma cell

FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma

Trials: MajesTEC-1, MajesTEC-1
Drug: Tecvayli (teclistamab-cqyv) · Anti-BCMA-CD3 bispecific antibody
Condition: Plasma cell